Author: Ravi Shankar

Company Announcement

Copenhagen, 26 October 2026
No. 65/2026

ISS A/S, a leading workplace experience and facility management company, announced on 19 February 2026 a new share buyback programme, see company announcement no. 10/2026. The share buyback programme is executed in accordance Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 (the “Market Abuse Regulation”) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, also referred to as the Safe Harbour Regulation.

Through the programme, ISS wishes to redistribute excess cash to shareholders. The purpose of the share buy-back programme is to (i) reduce the share capital and (ii) meet obligations arising from ISS’ share-based incentive programmes.

Under the programme, ISS will repurchase shares for a maximum consideration of DKK 3.1 billion, including approx. DKK 1.25 billion related to the completed first tranche, over a 12-month period from 19 February 2026 to 22 February 2027 at the latest, both days inclusive. The second tranche of up to DKK 1.85 billion commenced on 11 August 2026 and will complete no later than 22 February 2027.

The following transactions have been made under the programme:

	Number of shares	Average purchase price, DKK	Transaction value, DKK
Accumulated, last announcement	7,115,873	264.88	1,884,869,399
19 October 2026	54,000	295.94	15,980,760
20 October 2026	30,000	293.55	8,806,500
21 October 2026	53,000	295.16	15,643,480
22 October 2026	28,102	291.45	8,190,328
23 October 2026	52,000	288.48	15,000,960
Accumulated under the programme	7,332,975	265.72	1,948,491,427

Following the transactions stated above, ISS A/S owns a total of 7,081,350 treasury shares corresponding to 4.43% of the total share capital.

In accordance with the Market Abuse Regulation, the details of each transaction made under the share buyback programme are enclosed.

For investor enquiries
Michael Vitfell-Rasmussen, Head of Group Investor Relations, +45 53 53 87 25
Anne Sophie Riis, Senior Investor Relations Manager, +45 30 52 94 68

For media enquiries
Charlotte Holm, Head of External Communication, +45 41 76 19 89

ISS is a leading, global provider of workplace and facility service solutions. In partnership with customers, ISS drives the engagement and well-being of people, minimises the impact on the environment, and protects and maintains property. ISS brings all of this to life through a unique combination of data, insight and service excellence at offices, factories, airports, hospitals and other locations across the globe. ISS has more than 325,000 employees around the globe, who we call “placemakers”. In 2025, Group revenue was DKK 84.7 billion. For more information on the ISS Group, visit www.issworld.com

Attachments

• ISS announcement – SBB week 43
• Appendix_Company_Announcement_NO_43-2026

RENO, Nev., Oct. 26, 2026 (GLOBE NEWSWIRE) — Comstock Inc. (NYSE American: LODE) (“Comstock” and the “Company”) is pleased to announce that the Company’s CEO, Corrado De Gasperis, and CFO, Judd Merrill will provide an overview of our third quarter 2026 financial results and current business updates on Wednesday, November 4, 2026, at 4:30pm ET. We invite our investors and all other interested parties to register for the webinar at the link below.

Date: Wednesday, November 4, 2026
Time: 4:30pm ET
Register: Webinar Registration

The call includes a live presentation and a Q&A session. You may submit your question(s) beforehand in the registration form (linked above) or by email at: ir@comstockinc.com.

About Comstock Inc.

Comstock Inc. (NYSE: LODE) innovates and commercializes technologies, systems and supply chains that enable, support and sustain clean energy systems by efficiently, effectively, and expediently extracting and converting under-utilized natural resources into reusable metals, like silver, aluminum, and other critical minerals, primarily from end-of-life photovoltaics and renewable fuels, chemicals and animal feedstocks, primarily derived from proprietary crops and other forms of woody biomass for energy.

To learn more, please visit www.comstock.inc.

Comstock Social Media Policy

Comstock Inc. has used, and intends to continue using, its investor relations link and main website at www.comstock.inc in addition to its X.com, LinkedIn and YouTube accounts, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts

For investor inquiries:
Judd B. Merrill, Chief Financial Officer
Tel (775) 413-6222
ir@comstockinc.com

For media inquiries:
Zach Spencer, Director of External Relations
Tel (775) 847-7573
media@comstockinc.com

Forward-Looking Statements 

This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “forecast,” “seek,” “target,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future market conditions; future financial, natural, and social gains; future prices and sales of, and demand for, our products and services; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land and asset sales; investments, acquisitions, joint ventures, strategic alliances and business combinations; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings of equity or debt securities; and future working capital needs, revenues, variable costs, throughput rates, operating expenses, debt levels, cash flows, margins, taxes and earnings. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company or any other issuer.

• Combined company expected to advance differentiated oral obesity franchise led by CX11, a clinical-stage, once-daily oral small-molecule GLP-1 receptor agonist (“RA”), and CX12, a preclinical oral small-molecule amylin receptor agonist.
• CX11 has demonstrated clinically meaningful weight loss and a generally favorable tolerability profile across Phase 2 obesity studies in the United States. Following an End-of-Phase 2 meeting, Corxel US has aligned with the U.S. Food and Drug Administration (“FDA”) on key elements of CX11’s regulatory path and Phase 3 trial design.
• Institutional investors have committed to a private investment in public equity (“PIPE”) of approximately $300 million, with participation from new and existing investors including RTW Investments, New Enterprise Associates (NEA), SR One, Mirae Asset Capital Life Science, HBM Healthcare Investments (Cayman) Ltd., Nantahala Capital, Coastlands Capital, LifeSci Venture Partners, Invus, TCGX, RA Capital Management, Propel Bio, SilverArc Capital and a large healthcare mutual fund.
• Transaction expected to provide approximately $377 million in gross proceeds (prior to the payment of transaction costs and assuming no redemptions by Amanat shareholders).
• Business combination expected to be completed in the first half of 2027. Proceeds expected to support the company through 2029, including funding the planned global Phase 3 development program for CX11 in obesity.

BERKELEY HEIGHTS, N.J. and WESTFIELD, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) — Corxel Pharmaceuticals, Inc. (“Corxel US”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for obesity and related cardiometabolic conditions, and Amanat Acquisition Corp (Nasdaq: AMAN) (“Amanat”), a publicly traded special purpose acquisition company, today announced they have entered into a definitive business combination agreement.

Upon completion of the proposed transaction, Corxel US will become a wholly owned subsidiary of the combined public company. The combined public company is expected to operate under a new name and have its common stock listed on the Nasdaq Capital Market under a new ticker symbol, in each case to be announced before closing. The current management of Corxel US is expected to continue leading Corxel US while a search for a U.S.-based Chief Executive Officer is underway. A new Chief Executive Officer of the combined company is expected to be hired prior to or upon the closing of the transaction.

In addition to approximately $75 million held in Amanat’s trust account, the transaction includes commitments for a concurrent, oversubscribed PIPE that is expected to result in total gross proceeds of approximately $300 million, subject to adjustment pursuant to the reduction mechanism described below. The PIPE includes participation from new and existing investors including RTW Investments, New Enterprise Associates (NEA), SR One, Mirae Asset Capital Life Science, HBM Healthcare Investments (Cayman) Ltd., Nantahala Capital, Coastlands Capital, LifeSci Venture Partners, Invus, TCGX, RA Capital Management, Propel Bio, SilverArc Capital and a large healthcare mutual fund. Certain investors may receive pre-funded warrants in lieu of shares, priced at the per share price less the exercise price payable upon exercise. Subject to specified conditions, PIPE investors may also reduce their respective subscription obligations on a one-for-one basis by acquiring and not redeeming Amanat shares in the open market or in privately negotiated transactions prior to the shareholder meeting, with a corresponding reduction in their respective purchase prices under the PIPE.

“This transaction represents another important milestone in Corxel Group’s corporate evolution and reflects the significant progress we have made in building a globally competitive cardiometabolic pipeline,” said Sandy Mou, Executive Director and Chief Executive Officer of Corxel Group. “Corxel Group was built on the belief that our most promising pipeline deserves the focus and resources to reach its full potential. We believe the proposed business combination will mark Corxel US’s transition into an independent public company, positioning it to pursue its long-term growth strategy with greater visibility and broader access to the public markets.”

Kevin Xie, Ph.D., Chief Financial Officer of Corxel US, added, “This transaction represents an important step in establishing Corxel US as a publicly traded, obesity-focused biopharmaceutical company with the capital strength and strategic flexibility to advance CX11 through global pivotal development. We believe CX11’s clinical profile, including the weight loss and favorable tolerability observed across multiple studies, positions it as a potentially differentiated, next-generation oral GLP-1 therapy. Following an End-of-Phase 2 meeting, we have aligned with the FDA on key elements of CX11’s regulatory path and Phase 3 trial design, and we are preparing to advance CX11 into global pivotal Phase 3 trials. Together with CX12, CX11 provides the foundation for an oral obesity franchise built to deliver meaningful benefits to a broad global patient population.”

Pavan Cheruvu, M.D., Chief Executive Officer and Director of Amanat, added, “We established Amanat to identify compelling healthcare businesses that could benefit from our team’s operating, clinical, and capital-markets experience. We believe Corxel US brings together an experienced global development team, a late-stage oral GLP-1 program supported by a substantial clinical dataset, a favorable tolerability profile and a defined regulatory path, as well as an emerging oral amylin program. We believe the proposed transaction can provide the resources and public-company platform needed to advance this portfolio and create long-term value for patients and shareholders.” 

Building a Differentiated Oral Obesity Franchise

Corxel US is advancing a portfolio of oral product candidates designed to address important limitations of current injectable and oral obesity therapies and expand the number of patients who can access effective, convenient, and scalable treatment options.

Its lead product candidate, CX11, is an investigational, once-daily, oral small-molecule GLP-1 RA being developed for obesity, type 2 diabetes, and related cardiometabolic conditions. CX11 has been evaluated across an extensive clinical development program in the United States and Asia and has demonstrated clinically meaningful weight loss and a generally favorable tolerability profile.

In a U.S. Phase 2 obesity trial, CX11 achieved mean body-weight reduction of up to 11.5% at Week 36 under the efficacy estimand. CX11 also demonstrated a generally favorable GI tolerability and safety profile throughout the 36-week double-blind treatment period. Across the CX11 dosing cohorts, rates of nausea ranged from 33% to 34%, vomiting from 12% to 16%, diarrhea from 4% to 12% and constipation from 2% to 12%. The most commonly reported adverse events were GI-related and were generally mild to moderate in severity. No severe cases of nausea, vomiting, diarrhea or constipation were reported. GI adverse events occurred primarily during dose escalation and gradually subsided during the maintenance period. The overall treatment-discontinuation rate due to GI adverse events was 5.0%.

Following an End-of-Phase 2 meeting, Corxel US has aligned with the FDA on key elements of CX11’s regulatory path and Phase 3 trial design and plans to advance CX11 into global Phase 3 development.

An ongoing Phase 1b study evaluating higher doses of CX11 is expected to provide additional clinical data in the first half of 2027 and is intended to explore potential efficacy upside supported by the product candidate’s pharmacokinetic and tolerability profile observed to date.

Corxel US is also developing CX12, an investigational oral small-molecule amylin receptor agonist. Multiple lead candidates are currently under evaluation, with IND-enabling activities ongoing to target an investigational new drug application for CX12 in the first half of 2027. 

Transaction Overview

The proposed business combination and concurrent PIPE are expected to provide approximately $377 million (prior to the payment of transaction costs and assuming no redemptions by Amanat’s shareholders) in gross proceeds to the combined company. The net proceeds from the proposed transaction are expected to support the company through 2029 and to fund the global Phase 3 development program for CX11 in obesity.

Corxel Pharmaceuticals Limited (“Corxel Group”), the current parent company of Corxel US, is expected to receive equity consideration in the combined company in the form of common stock and pre-funded warrants.

The transaction is specifically limited to Corxel US and the obesity-focused business and assets included in the definitive business combination agreement. Corxel US is currently part of the broader Corxel Group. Other Corxel Group entities and assets held outside Corxel US, including Corxel HK and JX10, Corxel HK’s clinical-stage acute ischemic stroke program, are not included in the transaction and will remain outside the combined public company.

The boards of directors of Corxel US and Amanat have each approved the proposed transaction. The transaction is expected to close in the first half of 2027, subject to customary closing conditions, including, among other things, approval by Amanat’s shareholders, receipt of required approvals from Corxel US and Corxel Group stakeholders, effectiveness of the applicable registration statement, satisfaction of Nasdaq listing requirements and receipt of any required regulatory approvals.

 Additional information regarding the proposed transaction, including a copy of the definitive business combination agreement, will be included in a Current Report on Form 8-K to be filed by Amanat with the U.S. Securities and Exchange Commission (“SEC”) and will be available at the SEC’s website at www.sec.gov.

Advisors

Leerink Partners is acting as lead placement agent, and Evercore ISI, Guggenheim Securities, Cantor and LifeSci Capital are acting as placement agents for the PIPE financing. Leerink Partners is acting as capital markets advisor to Amanat.

Cooley LLP is serving as legal counsel to Corxel US and Corxel Group. Goodwin Procter LLP is serving as legal counsel to Amanat. Latham & Watkins LLP is serving as legal counsel to the placement agents. 

About Corxel US

Corxel US is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for obesity and related cardiometabolic conditions. Its lead product candidate, CX11, is an investigational, once-daily oral small-molecule GLP-1 receptor agonist that has completed Phase 2 clinical development in the United States and Phase 3 clinical development in Asia, demonstrating clinically meaningful weight loss and a generally favorable tolerability profile. Following an End-of-Phase 2 meeting, Corxel US has aligned with the FDA on key elements of CX11’s regulatory path and Phase 3 trial design. Corxel US is also advancing CX12, an investigational oral small-molecule amylin receptor agonist in preclinical development.

Corxel US is currently part of the Corxel Group. Corxel US and Corxel HK are separate entities within that group. The transaction with Amanat relates only to Corxel US and the obesity-focused business and assets specified in the definitive transaction documents. Corxel HK, JX10 and other assets held outside Corxel US are not part of the transaction. 

About Amanat Acquisition Corp

Amanat Acquisition Corp is a blank check company incorporated as a Cayman Islands exempted company for the purpose of completing a merger, amalgamation, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination.

Amanat intends to focus on opportunities in healthcare and healthcare-related industries that can benefit from the experience and capabilities of its management team and board of directors. Amanat is sponsored by Amanat Sponsor Holdings LLC and is led by Sandeep C. Kulkarni, M.D., Chairman of the Board; Pavan Cheruvu, M.D., Director and Chief Executive Officer; and Nicholas Fernandez, Chief Financial Officer. Amanat’s board of directors also includes Brad Middlekauff, Patrick Crutcher and Rakhi Kumar, bringing extensive experience across biotechnology investing, company building, financial leadership, corporate governance, business development, and capital markets.

Important Information About the Proposed Transaction and Where to Find It

The proposed transaction will be submitted to Amanat’s shareholders for consideration. In connection with the proposed transaction, Amanat intends to file with the SEC a registration statement on Form S-4 (the “Registration Statement”), which will include a preliminary proxy statement for the solicitation of proxies from Amanat shareholders with respect to the proposed business combination and other matters to be described in the Registration Statement and a prospectus relating to securities expected to be issued in the proposed transaction.

After the Registration Statement has been filed and declared effective, Amanat expects to mail or otherwise make available to shareholders entitled to vote a definitive proxy statement/prospectus and other relevant materials. This announcement is not a substitute for the Registration Statement, proxy statement/prospectus or any other document that may be filed with the SEC in connection with the proposed transaction.

AMANAT SHAREHOLDERS AND OTHER INTERESTED PERSONS SHOULD REVIEW CAREFULLY, WHEN AVAILABLE, THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS, ANY AMENDMENTS OR SUPPLEMENTS, AND OTHER RELEVANT SEC FILINGS BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, BECAUSE THOSE MATERIALS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES.

When available, these documents may be obtained without charge through the SEC’s website at www.sec.gov or by directing a request to Amanat Acquisition Corp, 153 Central Avenue, C/O 56, Westfield, New Jersey 07091. 

Participants in the Solicitation

Amanat, Corxel US and certain of their respective directors, executive officers and other members of management and employees may be considered participants in the solicitation of proxies from Amanat shareholders in connection with the proposed transaction.

Information regarding Amanat’s directors and executive officers, including their interests by security holdings or otherwise, is available in Amanat’s SEC filings, which may be obtained without charge through the SEC’s website at www.sec.gov or by directing a request to Amanat Acquisition Corp, 153 Central Avenue, C/O 56, Westfield, New Jersey 07091. Additional information concerning the persons who may be considered participants and a description of their direct and indirect interests in the proposed transaction will be included in the Registration Statement and proxy statement/prospectus when filed. Shareholders, potential investors and other interested persons should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. 

No Offer or Solicitation

This announcement is provided solely for informational purposes and is not, and under no circumstances is to be construed as, a proxy statement, a solicitation of any proxy, consent or authorization, a recommendation concerning any securities or the proposed transaction, a prospectus, an advertisement or a public offering of the securities described herein in the United States or any other jurisdiction. This announcement shall not constitute an offer to sell or exchange, or a solicitation of an offer to buy or exchange, or a recommendation to purchase, any securities, in any jurisdiction, or the solicitation of any vote, consent or approval in any jurisdiction in connection with the proposed business combination or any related transactions, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful.

No sale of securities will be made in any jurisdiction where the offer, solicitation or sale would be unlawful before registration or qualification under applicable securities laws. Any offering of securities will be made only through a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or pursuant to an available exemption from registration.

THE SEC AND ANY STATE SECURITIES COMMISSION HAVE NOT APPROVED OR DISAPPROVED THE SECURITIES REFERRED TO IN THIS ANNOUNCEMENT, PASSED ON THE MERITS OF THE PROPOSED TRANSACTION OR DETERMINED THAT THIS ANNOUNCEMENT IS ACCURATE OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL. 

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of applicable U.S. federal securities laws. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “seek,” “should,” “will,” “would” and similar expressions, although not all forward-looking statements contain these identifying words. These statements include, but are not limited to, statements regarding the proposed business combination and PIPE financing; the anticipated timing, structure, proceeds, ownership, capitalization, management, listing and expected benefits of the proposed transaction; statements regarding estimates and forecasts of other financial and performance metrics and projections of market opportunity; the parties’ ability to complete the transaction and satisfy closing conditions; the anticipated use of proceeds and cash runway; and the development, regulatory, manufacturing and commercialization plans for CX11, CX12 and other product candidates, including the design, timing, enrollment and results of clinical trials and the potential efficacy, safety, tolerability, convenience, scalability and commercial opportunity of those product candidates.

These statements reflect current expectations and assumptions as of the date of this announcement, are provided for illustrative purposes only and are not guarantees or predictions of future performance.

Actual results may differ materially because of numerous risks and uncertainties, many of which are difficult or impossible to predict or are beyond the parties’ control. These risks include, but are not limited to: the possibility that the proposed transaction is delayed, restructured or not completed; failure to obtain shareholder, regulatory or other approvals or to satisfy other closing conditions; the amount of Amanat shareholder redemptions; changes in the amount of cash available to the combined company; failure to satisfy Nasdaq listing requirements; the occurrence of events giving rise to termination rights under the definitive agreement; litigation or other proceedings relating to the transaction; costs and disruption arising from the announcement or completion of the transaction; adverse changes in business, market, economic, political or regulatory conditions; volatility in the combined company’s securities; dilution resulting from the transaction or future financings; the outcome of any legal proceedings that may be instituted against Amanat or Corxel US related to the proposed business combination; the inability of the parties to successfully or timely consummate the proposed business combination and other related transactions, including the risk that any regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the proposed business combination and other related transactions; and the combined company’s ability to realize the anticipated benefits of the transaction and manage growth. 

Additional risks include uncertainties inherent in drug research and development, clinical trials and regulatory review; delays or difficulties in patient enrollment, manufacturing or supply; clinical results that do not support continued development or approval; the timing and outcome of interactions with regulatory authorities; competition; dependence on third-party manufacturers, clinical research organizations and other service providers; intellectual-property risks; the ability to attract and retain key personnel; and the need for additional financing. This list is not exhaustive.

Further information about risks and uncertainties will be included in the Registration Statement and proxy statement/prospectus for the proposed transaction and in other filings made by Amanat with the SEC, including under the captions addressing risk factors. Readers should not place undue reliance on forward-looking statements, which speak only as of the date made. Except as required by applicable law, Amanat and Corxel US do not undertake to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts

Corxel US Investor Relations
Ray Lyu
Ray.Lyu@corxelbio.com

Corxel US Media Relations
Madelin Hawtin
Mhawtin@lifescicomms.com 

Amanat Acquisition Corp
Nicholas Fernandez
Nfernandez@amanat.bio 

• TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable effect in combination with standard-of-care, and a tolerability profile supportive of systemic administration in an outpatient setting
• With median follow-up of 12.7 months, objective response rate (ORR) for the squamous cohort was 72% and disease control rate (DCR) was 100%, with a median duration of response of 12.9 months and multiple participants continuing in active follow-up
• TeLuRide-008, an ongoing adaptive Phase 2/3 trial of EIK1001 in NSCLC, actively enrolling, with a prespecified interim analysis for dose selection anticipated in 2H 2027

MILLBRAE, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) — Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the presentation of updated data for EIK1001 at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain.

“These updated results presented at ESMO from the squamous NSCLC cohort build on the mature non-squamous cohort data presented at ASCO and further support the potential of adding EIK1001 to pembrolizumab and chemotherapy,” said Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon. “The observed response and disease control rates, as well as a 12.9-month median duration of response, are encouraging, with several patients remaining in active follow-up. These findings support continued evaluation of this combination for patients with advanced NSCLC.”

EIK1001 Clinical Update:

Updated data from the open-label TeLuRide-005 trial evaluating TLR7/8 dual-agonist EIK1001 in combination with both pembrolizumab and histology-appropriate chemotherapy in participants with advanced NSCLC demonstrates potentially durable effect of EIK1001 in combination with standard of care, as well as a tolerability profile supportive of systemic administration in an outpatient setting, a potential key differentiator of EIK1001 from previous TLR7/8 targeted therapies.

In TeLuRide-005, 72 participants with previously untreated stage 4 NSCLC received intravenous EIK1001 once-weekly (QW) combined with standard of care pembrolizumab plus histology-appropriate chemotherapy once every third week (Q3W). After 8 cycles, EIK1001 administration was reduced to Q3W. The maximum treatment duration is 2 years (up to 35 cycles) for EIK1001 in combination with pembrolizumab, with pemetrexed continued at the discretion of the Investigator for non-squamous participants.

At the July 13, 2026, safety data cutoff, among the safety evaluable population (n=72: 39 non-squamous; 33 squamous), the combination of EIK1001 with pembrolizumab and chemotherapy was generally well tolerated, with an adverse event (AE) profile similar to standard-of-care alone. Grade 3 or higher treatment-related adverse events (TRAEs) occurred in 48.6% of participants, and TRAEs led to treatment discontinuation in 6.9%. The most common Grade 3 or higher TRAEs were neutropenia (30.6%), anemia (9.7%), and thrombocytopenia (9.7%). Cytokine release syndrome events were all low-grade (Grade 1, n=5; Grade 2, n=2), and there were no Grade 3 or higher events. There were no TRAEs that led to death. This profile was sufficient to support administration in an outpatient setting during the ongoing trial.

Among the efficacy-evaluable population (n=65: 36 non-squamous; 29 squamous), EIK1001 treatment in combination with pembrolizumab and chemotherapy pooled data with a median follow-up of 17.2 months resulted in a 63.1% objective response rate (ORR) and 89.2% disease control rate (DCR) at the efficacy data cutoff of October 1, 2026. Objective responses were observed across all PD-L1 tumor proportion score (TPS) subgroups. Among participants in the squamous cohort, an ORR of 72.4% and a DCR of 100% were observed, respectively, with a median follow-up of 12.7 months and a median duration of response (DOR) of 12.9 months at the efficacy data cutoff. Among participants in the non-squamous cohort, an ORR of 55.6% and a DCR of 80.6% were observed, respectively, with a median follow-up of 17.9 months. The median DOR in the non-squamous cohort was 11.2 months at the efficacy data cutoff.

In addition to the TeLuRide-005 data presented at ESMO, Eikon is currently conducting a Phase 2/3 registrational trial of EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy in systemic therapy-naïve participants with stage 4 non-squamous or squamous NSCLC, also known as TeLuRide-008 (NCT07365319). Eikon expects to conduct a first interim analysis to select the single dose of EIK1001 to take forward for the remainder of this trial in the second half of 2027.

About Eikon Therapeutics
Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully integrated organization developing innovative medicines to address serious unmet medical needs. Eikon’s initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon’s vision is to become a generational leader by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. For more information, visit www.eikontx.com.

About NSCLC
Lung cancer is one of the most common cancers globally, with NSCLC making up 80% to 85% of all lung cancer cases. NSCLC is often diagnosed at advanced stages when treatment options are more limited and there remains significant unmet medical need in this patient population. The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. The current standard of care for stage 4 NSCLC, combining immune checkpoint inhibitors (ICIs) (e.g., pembrolizumab) plus histology-appropriate chemotherapy confers significant clinical benefit over chemotherapy alone, yet many patients progress nonetheless, highlighting the large unmet medical need in the management of this disease.

About EIK1001
EIK1001 is an investigational, systemically administered dual-agonist of Toll-like receptors 7 and 8, designed to stimulate both innate and adaptive immune responses. In Phase 1 trials of EIK1001, single-agent activity was observed in patients with advanced malignancy. This mechanism may complement the anti-tumor immune response engendered by PD-(L)1 blockade. EIK1001 has been studied in over 600 participants and observed to be well-tolerated to date, both as a monotherapy and in combination with PD-(L)1-specific antibody-based therapy.

About TeLuRide-005
TeLuRide-005 (NCT06246110) is a multicenter, open-label trial of once-weekly (QW) systemically administered EIK1001 in combination with standard of care, once every third week (Q3W) pembrolizumab and histology-appropriate chemotherapy in first-line, treatment-naïve participants with stage 4 NSCLC. Enrollment completed in the first quarter of 2026.

Forward-Looking/Safe Harbor Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts are hereby identified as forward-looking statements for this purpose. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential, safety, and efficacy of Eikon’s product candidates; the potential to further develop Eikon’s product candidates; the timing for anticipated data readouts; expected milestones and business objectives, including Eikon’s anticipated presentations at the 2026 ESMO Congress; and other statements regarding Eikon’s future operations, financial performance, financial position, prospects, objectives, strategies and other future events.

These forward-looking statements are based upon management’s current expectations and assumptions, and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: our limited operating history; our significant net losses incurred since inception and the likelihood of incurring additional losses for the foreseeable future; our need for substantial additional funding; the early stage of development of many of our product candidates and the possibility that our product candidates may fail in development; our dependence on the success of our current product candidates; our ability to leverage our technology platform to enable more informed drug research and development; legal and regulatory risks; intellectual property-related risks; and those risks, uncertainties and other factors discussed under the caption “Risk Factors” and elsewhere in Eikon’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission (“SEC”) on August 13, 2026, and in other public filings with the SEC in the future.

As a result, you should not place undue reliance on any forward-looking statements. The forward-looking statements made in this press release speak only as of the date of this press release, and Eikon undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.

Contacts:

Investors
Alfred “Freddie” Bowie, Ph.D., CFO
ir@eikontx.com

Media
Colin Sanford
colin@bioscribe.com

VANCOUVER, British Columbia, Oct. 26, 2026 (GLOBE NEWSWIRE) — SNOWLINE GOLD CORP. (TSX: SGD) (US OTCQB: SNWGF) (the “Company” or “Snowline”) is pleased to announce the appointment of Randy Smallwood to its Board of Directors (the “Board”) as an Independent Director, effective today. Mr. Smallwood brings further mining, corporate development and finance experience to Snowline’s Board. He is the non-executive Chair of Wheaton Precious Metals Corp. (“Wheaton”) where, as President and CEO he led the company through a period of remarkable growth from 2011 to 2026.

“We are pleased to welcome Randy to our Board as a recognized builder in the gold industry,” said Craig Hart, Chair of Snowline’s Board. “His several decades of experience will bring new dimensions of expertise to our Board.”

“Mr. Smallwood’s reputation as an entrepreneur and corporate leader in our industry is well earned, and he adds valuable perspective as Snowline continues to advance and grow,” said Scott Berdahl, CEO. “Importantly, his longstanding commitment to responsible development, community investment and philanthropy strongly align with the values that guide Snowline.”

“I am excited about the opportunity to join the Snowline team and to help them advance the Rogue Project,” said Mr. Smallwood. “The Valley deposit has the potential to become one of Canada’s largest gold mines and a major contributor to the Yukon economy.”

Mr. Smallwood was a co-founder of Wheaton (formerly Silver Wheaton Corp.) in 2004 and served as President and CEO from 2011 to March 2026. Previously he led project evaluation and corporate development for Wheaton River Minerals Ltd./Goldcorp and was Project Manager for the Golden Bear Mine in northern B.C. from 1995 to 2000.

He remains active on the World Gold Council, having served as Chair (2020-2023), and with the Canadian Institute of Mining, Metallurgy and Petroleum (CIM) where he is the incoming President-Elect.

Randy’s commitment to the community includes his support of various philanthropic endeavours with Special Olympics BC, MineralsEd BC, and Mining4Life, and previously the BC Cancer Foundation board.

Mr. Smallwood holds a geological engineering degree (1995) and an Alumni Medal of Distinction (2026) from the University of British Columbia, along with a mine engineering diploma (1992) and a Distinguished Alumni Award (2015) from the British Columbia Institute of Technology.

ABOUT SNOWLINE GOLD CORP.

Snowline Gold Corp. is a Yukon Territory gold exploration and development company focused on advancing its 100% owned Valley gold deposit on its flagship Rogue Project, while unlocking district upside on its 360,000 ha (3,600 km²) mineral tenure in the highly prospective yet underexplored Selwyn Basin.

Valley is a large, low strip, near surface, >1 g/t Au bulk tonnage gold system hosting an open MRE of 7.94 million ounces gold at 1.21 g/t Au Measured & Indicated (in 204.0 million tonnes)¹ and an additional 0.89 million ounces gold Inferred at 0.62 g/t Au (in 44.5 million tonnes)², with a cut-off grade of 0.3 g/t Au. Results of a PEA for Valley suggest the potential to support a long-life mining operation with a strong production profile and low production costs. The MRE and PEA are detailed in the recent technical report for Rogue, prepared in accordance with NI 43-101 (as defined below) standards, entitled “Independent Preliminary Economic Assessment for the Rogue Project Yukon, Canada,” dated August 27, 2025, with an effective date of March 1, 2025, and available on SEDAR+ and the Company’s website (the “Technical Report”). The PEA is preliminary in nature and includes Inferred Mineral Resources that are considered too speculative geologically to have economic considerations applied to them that would enable classification as Mineral Reserves. There is no certainty that the results of the PEA will be realized. Work is underway on a PFS to supersede the Valley PEA on completion, anticipated in Q1 2027.

Snowline’s project portfolio sits within the prolific Tintina Gold Province, host to multiple million-ounce-plus gold mines and deposits across the central Yukon and Alaska. The Company’s comprehensive first-mover position and extensive exploration database provide a distinct competitive advantage and a unique opportunity for investors to be part of multiple discoveries, the advancement of a significant gold deposit, and the creation of a new gold district.

QUALIFIED PERSON

Information in this news release has been prepared under supervision of and approved by Thomas Branson, M.Sc., P. Geo., VP Exploration for Snowline, as Qualified Person for the purposes of NI 43-101.

ON BEHALF OF THE BOARD

Craig Hart
Independent Chair & Director

Scott Berdahl
CEO & Director

For further information, please contact:

Snowline Gold Corp.
+1 778 650 5485
info@snowlinegold.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This news release contains certain forward-looking statements, including statements regarding advancement of the Valley deposit and the Rogue Project; Valley’s potential to become one of Canada’s largest gold mines and a major contributor to the Yukon economy; the potential for a long-life mining operation with a strong production profile and low production costs; the anticipated completion of the PFS in Q1 2027; continued exploration; potential discoveries; and the creation of a new gold district. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof.

Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. Such factors include, among other things: risks related to uncertainties inherent in drill results and the estimation of mineral resources; and risks associated with executing the Company’s plans and intentions. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this news release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

                            

¹ Comprising 3.15 million ounces at 1.41 g/t Au in Measured and 4.79 million ounces at 1.11 g/t Au in Indicated.

² Mineral resources are not mineral reserves and do not have demonstrated economic viability. The estimate of mineral resources may be materially affected by metal prices, economic factors, environmental, permitting, legal, title, or other relevant issues.

Press Release

Atos launches Atos Genesis Intelligence suite featuring Atos Codex to address the full AI application spectrum

As the culmination of the Atos Genesis Intelligence suite, Atos Codex turns operational data into trusted real-time decisions and actions for mission-critical environments.

Paris, France, October 26, 2026 – Atos, a global leader in digital transformation and artificial intelligence, today announces Atos Genesis Intelligence, a comprehensive AI suite designed to help organizations accelerate AI adoption and transform data into measurable business outcomes. By bringing together sovereign data management, advanced AI capabilities, secure orchestration and governance within a single ecosystem, the suite enables enterprises to move faster from experimentation to production, simplify complex technology landscapes and scale trusted and frugal AI across the full spectrum of critical business operations.

Built for organizations operating in highly regulated and data-sensitive environments, Atos Genesis Intelligence provides the foundation to innovate faster, improve decision-making, increase operational efficiency and maintain full control over data, infrastructure and compliance requirements. Deployable across public cloud, sovereign cloud, on-premises and air-gapped environments, the suite combines flexibility, security and sovereignty without compromise.

Bridging the gap between AI insights and mission-critical operational outcomes with Atos Codex

Alongside the suite, Atos is introducing Atos Codex, the ultimate expression of Atos Genesis Intelligence. Atos Codex, which stands for Center of Operations and Data EXcellence, is designed for organizations operating in mission-critical environments, and transforms data, expertise and AI insights into trusted actions executed within a secure and governed environment.

While many AI initiatives stop at recommendations, Atos Codex helps organizations move from knowing to acting. By connecting data, operational context, cybersecurity controls and AI-driven reasoning within a single platform, it enables faster, more informed and more consistent decision-making across mission-critical operations.

Built on Atos’ decades of experience operating some of the world’s most complex and sensitive environments, as well as on Eviden’s expertise in cybersecurity products and mission-critical systems, the platform helps critical infrastructure operators, transportation providers, industrial organizations, defense agencies and public sector institutions improve responsiveness, optimize operations and strengthen resilience while maintaining human oversight and governance.

By continuously connecting information, context, intelligence and execution, Atos Codex enables organizations to shorten decision cycles, improve operational performance, and react more effectively to changing conditions. The result is greater operational agility, stronger resilience, and better business outcomes delivered within a secure and governed framework.

Atos Codex creates a structured representation of the organization’s operational environment including its entities, relationships, rules, permissions and possible actions – an operational ontology that provides a shared context for users, data and AI.  Insights and decisions can then be translated into operational actions, based on the governance model and the level of human control defined by the organization.  

“Organizations are looking beyond AI experimentation and increasingly focusing on tangible business outcomes. With Atos Genesis Intelligence, we provide an end-to-end sovereign and trusted foundation that helps our customers accelerate AI adoption, reduce complexity and deliver measurable value faster across the full AI lifecycle. As the culmination of the suite, Atos Codex extends this vision by enabling mission-critical organizations to turn trusted insights into operational actions, helping them become more efficient, resilient and competitive while maintaining full control over their critical data and operations,” said Philippe Salle, Chairman and CEO of Atos Group.

More information about Atos Genesis Intelligence suite

Atos Genesis Intelligence is a comprehensive end-to-end AI suite designed to help organizations accelerate AI adoption while maintaining sovereignty, security and governance across the entire AI lifecycle. Combining data management, AI model development and deployment, and orchestration capabilities within a single ecosystem, the suite provides the foundation required to industrialize AI initiatives, reduce deployment risks and scale them across the enterprise.

Key features include:

• Open and interoperable architecture, built on open-source technologies to provide flexibility, avoid vendor lock-in and accelerate innovation.
• Sovereign and flexible deployment options, supporting public cloud, sovereign cloud, on-premises and air-gapped infrastructures to meet the requirements of highly regulated organizations.
• Data Foundation for unifying and governing data throughout its lifecycle, from ingestion and preparation to transformation and analytics, with built-in data quality, cataloging, lineage and traceability.
• Enterprise-grade AI capabilities combining intelligent model routing and cost optimization to enable a more frugal use of AI, with secure AI orchestration and integrated governance, security and compliance controls.
• SLM Factory (Small Language Model Factory) for developing and managing locally deployable AI models, giving organizations greater control over their data and AI environments.
• Enterprise AI portal, providing secure access to a marketplace of GenAI agents that can be customized for specific business use cases.

The Atos Genesis Intelligence Suite is continuously enriched through the Atos Sovereign Agentic Studios, a global, production-first delivery model for real-world agentic AI deployment, incorporating field-proven innovations, accelerators and best practices.

***

About Atos

Atos is Atos Group’s brand dedicated to end-to-end, secure and AI-accelerated digital services. Atos designs, develops and operates digital environments that are critical to performance, resilience and sovereignty. The company helps public and private organizations around the world maintain control of their data and infrastructure, while meeting their compliance requirements.

With more than 51,000 employees serving more than 4,500 customers in 54 countries, Atos supports the modernization of IT systems, accelerates cloud and data transformation, strengthens cybersecurity and deploys secure digital workplaces for the benefit of its customers, their employees and society. Atos also offers consulting and support services through its Atos Amplify brand.

As a trusted partner in the management of complex and critical environments, Atos supports organizations in highly regulated and sovereign contexts.

About Atos Group

Atos Group is a global leader in digital transformation with nearly 53,000 employees and annual revenues of nearly €7.2 billion. With a commercial presence in 54 countries, it operates under two brands: Atos for services and Eviden for products and systems. As the European leader in cybersecurity and a leader in the cloud sector, Atos Group is committed to a secure and decarbonized future. It offers tailor-made and integrated solutions, accelerated by AI, for all sectors of activity. Atos Group is listed on Euronext Paris.

Press contact: Laurent Massicot – laurent.massicot@atosgroup.com

Attachment

• Global PR – Atos launches Atos Genesis Intelligence suite featuring Atos Codex to address the full AI application spectrum

ANNOUNCEMENT

A.P. Møller – Mærsk A/S – Transactions in connection with share buy-back program

On 5 February 2026, A.P. Møller – Mærsk A/S (the “Company”) announced a share buy-back program of up to DKK 6.3bn (around USD 1bn) to be executed over a period of 12 months. The second phase of the share buy-back program will run from 13 August 2026 up to 29 January 2027. The shares to be acquired will be limited to a total market value of DKK 3.15 billion (around USD 500m).

The share buy-back program will be executed under EU Commission Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”)

The following transactions have been made under the program in the period 19 October to 23 October 2026:                        

	Number of A shares	Average purchase price A shares, DKK	Transaction value, A shares, DKK
Accumulated, last announcement	50,148		861,977,700
19 October 2026	220	23,631.3636	5,198,900
20 October 2026	220	23,321.1818	5,130,660
21 October 2026	220	22,834.9091	5,023,680
22 October 2026	220	22,440.2727	4,936,860
23 October 2026	220	21,998.9091	4,839,760
Total 19-23 October 2026	1,100		25,129,860
Accumulated in the second phase of the program	13,000		284,753,190
Accumulated under the program	51,248		887,107,560
	Number of B shares	Average purchase price B shares, DKK	Transaction value, B shares, DKK
Accumulated, last announcement (market and the Foundation)	200,592		3,536,107,145
19 October 2026	771	24,490.9598	18,882,530
20 October 2026	771	24,160.9079	18,628,060
21 October 2026	771	23,518.8586	18,133,040
22 October 2026	771	23,145.2529	17,844,990
23 October 2026	771	22,655.5123	17,467,400
Total 19-23 October 2026	3,855		90,956,020
Bought from the Foundation*	545	23,594.2983	12,858,893
Accumulated in the second phase of the program (market and the Foundation)	52,000		1,182,053,783
Accumulated under the program (market and the Foundation)	204,992		3,639,922,058

*) According to a separate agreement, A.P. Møller og Hustru Chastine Mc-Kinney Møllers Familiefond (the Foundation) participates on a pro rata basis to the shares purchased in the share buy-back program.

With the transactions stated above, the Company owns a total of 51,248 A shares and 262,236 B shares as treasury shares, corresponding to 2.13% of the share capital.                                        
Details of each transaction are included as appendix.

Copenhagen, 26 October 2026

Contact persons:
Head of Investor Relations, Martin Dunwoodie, tel. +45 3363 3484
Head of Media Relations, Jesper Lov, tel. +45 6114 1521

Page 1 of 1

Attachments

• Announcement – Transactions in connection with share buy-back program – week 43 2026
• Daily transactions in connection with share buy-back program – week 43 2026

Stem.l
FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:	Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	SThree Plc
(c)        Name of the party to the offer with which exempt principal trader is connected:	Investec is Joint Broker to SThree Plc
(d)        Date dealing undertaken:	23rd October 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state “N/A”	N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Purchase	19,560	297	289.5
Ordinary shares	Sales	19,560	297	289.5

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)        the voting rights of any relevant securities under any option; or (ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	26th October 2026
Contact name:	Priyali Bhattacharjee
Telephone number:	+91-9768034903

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

CERTIFICATE MATURITY	261028
FIXED RATE (STEERING RATE + 10 b.p.)	1.85 %
VOLUME BOUGHT	25.0 BLN
TRADE DAY	261026
SETTLEMENT DAY	261027

To Nasdaq Copenhagen

26 October 2026

Financial calendar 2027 for the companies of the Nykredit Group

11 February
Publication of Annual Reports 2026 and announcements of Financial Statements of the Nykredit Realkredit Group, Totalkredit A/S (in Danish only) and the Nykredit Bank Group

18 March
Annual General Meeting of Totalkredit A/S, Sundkrogsgade 25, DK-2150 Nordhavn.

18 March
Annual General Meeting of Nykredit Bank A/S, Sundkrogsgade 25, DK-2150 Nordhavn.

18 March
Annual General Meeting of Nykredit Realkredit A/S, Sundkrogsgade 25, DK-2150 Nordhavn.

5 May
Publication of Q1 Interim Report 2027 of the Nykredit Realkredit Group.

19 August
Publication of H1 Interim Reports 2027 of the Nykredit Realkredit Group, Totalkredit A/S (in Danish only) and the Nykredit Bank Group.

4 November
Publication of Q1-Q3 Interim Report 2027 of the Nykredit Realkredit Group.
                                                                                                                                           

Contact
Nykredit Press Relations, tel +45 31 21 06 39

Attachment

• Financial calendar 2027 for the companies of the Nykredit Group